Related Experiment Video
Updated: May 10, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Breaking immune isolation in glioblastoma
1Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
Summary
Glioblastoma (GBM) is an immune-cold tumor resistant to current immunotherapies. This review explores multi-modal strategies to transform the GBM tumor microenvironment (TME) into an immune-active state for better treatment outcomes.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioblastoma (GBM) is a highly immunosuppressive, immune-cold tumor.
- Current immunotherapies show limited clinical benefit due to T-cell exclusion and myeloid-dominant tumor microenvironments (TME).
Purpose of the Study:
- To review emerging multi-modal strategies for reprogramming the GBM TME.
- To propose an integrated framework for overcoming therapeutic resistance in GBM.
Main Methods:
- Synthesis of evidence on innate immune agonists, oncolytic virotherapy, nanomedicine, metabolic modulation, and radiotherapy-immune synergies.
- Discussion of spatial immunomics, targeted delivery, and TME-specific engineering.
Main Results:
- Glioblastoma (GBM) exhibits profound immune suppression, hindering immunotherapy efficacy.
- Multi-modal strategies show promise in converting the immune-cold TME into an immunologically active state.
Conclusions:
- Reprogramming the GBM TME is crucial for enhancing immunotherapy response.
- An integrated approach combining advanced technologies may overcome GBM therapeutic bottlenecks.
